Mary Jo Laffler
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mary Jo Laffler
The Institute for Clinical and Economic Review has weighed in on the pros and cons of rebate reform, surveying an assortment of payers, pharmacy benefit managers and pharmaceutical companies on alternative rebate models and their potential impact.
Pfizer CEO Ian Read will preside over his last sales and earnings call as the big pharma's chief executive, while for GlaxoSmithKline, uncertainty lingers over the timing of a generic Advair. Amgen will have its second opportunity to talk to investors about its 60% Repatha price cut, while answering questions about Aimovig strategy and Neulasta biosimilars. And other topics to watch in the next earnings calls...
Keytruda continues to break records on the strength of its efficacy in lung cancer, and shows no signs of slowing down. But analysts were intrigued by repeated mentions of business development during Merck’s third quarter earnings call.